Basic Translational Clinical New Pathways to Discovery Harmonization Target ID & Valid. Phases I-III Research Teams of Future Translational Cores Clinical.

Slides:



Advertisements
Similar presentations
The NIH Roadmap for Medical Research
Advertisements

Dr Claes Wilhelmsson Executive Director Research & Development Innovation and the life sciences.
The Drug Discovery Process
The NIH Roadmap for Medical Research nihroadmap.nih.gov.
The post-genomic challenge Exploring function across protein families using chemical probes  The CPFM is in early stages of development  Projects focus.
Challenges in new drug discovery in South Asia
National Institute on Aging Judith A. Salerno, M.D., M.S. Deputy Director NIA/NIH/DHHS ADC Meeting April 2004.
“It is the responsibility of those of us involved in today’s biomedical research enterprise to translate the remarkable scientific innovations we are witnessing.
NIGMS Archived File The file below has been archived for historical reference purposes only. The content and links are no longer maintained and may be.
The NIH Roadmap.
1 NIH Clinical Center,CTSAs NIH Molecular Libraries Initiative Disease Target ID Assay Dev. HTS Probe to Lead Pre- Clinical FDA IND Ph. IPh. IIPh. III.
Brian C. Springer, MHA Executive Director Siteman Cancer Center Barnes-Jewish Hospital & Washington U. School of Med CCSG-CTSA Interactions Michael Bertram,
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Jeffery Loo NLM Associate Fellow ’03 – ’05 chemicalinformaticsforlibraries.
Strategies for the Lean Years Ruth Farrell, Associate VP for Research Administration.
NA shell NA shell vPFC mVP VTA NA core NA core dPFC SN dVP Blockade in these regions blocks relapse or reinstatement Drug Seeking Behavior – Motor Subcircuit.
Chemical Genetics – Biol503
Knowledge Commons: The Case of the Biopharmaceutical Industry Arti K. Rai Duke Law School.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Discussion Our current results suggest that it is possible to identify susceptibility regions using this methodology. The presented method takes advantage.
National Institute on Aging Richard J. Hodes, M.D. Director,NIA/NIH/DHHS ADC Meeting – NIH Roadmap and Budget October 2003.
High Throughput And High Content Screening. What Is HTS ? Biochemical target  Test many compounds  Compounds with desired effect on target = Hit  OR.
Molecular Library and Imaging Francis Collins, NHGRI Tom Insel, NIMH Rod Pettigrew, NIBIB Building Blocks and Pathways Francis Collins,NHGRI Richard Hodes,
The NIH Roadmap for Medical Research
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Drug discovery and development
TYPE 2 TRANSLATIONAL RESEARCH 2009 GRANT PROGRAMS UW Institute for Clinical and Translational Research (ICTR) Community-Academic Partnership Core (CAP)
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
NIH Roadmap for Medical Research and Common Fund Update on Recent Changes Dinah Singer, Ph.D. Director, Division of Cancer Biology June 18, 2008.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
NIH Roadmap and Chemoinformatics Jeffery Loo NLM Associate Fellow Welch Library Journal Club 2004/12/7.
Aberdeen Confidence in Concept Fund Prof Phil Hannaford Vice Principal – Research & Knowledge Exchange.
1 Introduction to Grant Writing Beth Virnig, PhD Haitao Chu, MD, PhD University of Minnesota, School of Public Health December 11, 2013.
ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH Notre Dame: Drug Discovery Expertise and Resources Chemical Structure and Synthetic.
CS 790 – Bioinformatics Introduction and overview.
Genome Research Institute University of Cincinnati.
Fochon Pharma “FOCHON” - Continuing Innovation/Creation F - Fluorine O - Oxygen C - Carbon H - Hydrogen O - Oxygen N - Nitrogen.
The NIH Roadmap and the Human Microbiome Project Francis S. Collins, M.D., Ph.D. National Human Genome Research Institute April 22, 2007.
NIH Roadmap for Medical Research
NIH Common Fund Library of Integrated Network- based Cellular Signatures LINCS Applicant Information Webinar for RFA-RM September 6, :00 –
24 September 2009National Academies - BRDI1 Research Data and Information: New Developments at NIH Jerry Sheehan Assistant Director for Policy Development.
Valentina Di Francesco Senior Program Officer for Bioinformatics, Structural Genomics and Systems Biology Microbial Genomics.
National Center for Research Resources G. Iris Obrams, M.D., M.P.H., Ph.D. NCRR Update 5 August 2006.
Decoding the Network Footprint of Diseases With increasing availability of data, there is significant activity directed towards correlating genomic, proteomic,
ECCR Overview/MLSCN. NIH Roadmap Series of initiatives designed to pursue major opportunities in biomedical research and gaps in current knowledge that.
Robert H. Wiltrout Director, CCR Director’s Address.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
University of Kentucky Center for Clinical and Translational Science (CCTS) November 2015 Stephen W. Wyatt, DMD, MPH Senior Associate Director Center for.
1 PLEASING CLIENTS AT A MOLECULAR AND CELLULAR LEVEL AUGUST 7, 2015.
NIH and the Clinical Research Enterprise Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institute of Health.
PubChem: An Open Repository for Chemical Structure and Biological Activity Information Steve Bryant The NIH Biowulf Cluster: 10 Years of Scientific Supercomputing.
Dr. Horst Hemmerle Eli Lilly & Company Director Lead Generation Technologies: Responsible for: Compound Collection Enrichment Strategy Screening Strategies.
High-Throughput Screening Core Facility at CU-Boulder Wei Wang
A truly integrated drug discovery company 26 th April 2016 CONFIDENTIAL.
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
BIO409/509 Cell and Molecular Biology.
전통적인 신약 개발 과정.
Nehad A. El Sayed, Amal A. H. Eissa, Reem K. Arafa and Ghada F. El Masry* Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University.
Page 1 Transporter Screening -Profacgen. Page 2 Transporters are a group of specialized membrane proteins that power the translocation of numerous substances,
Screening of allosteric inhibitors and inhibitors of protein-protein interactions Joel Eggert.
The U.S. National Center for Advancing Translational Sciences CHRISTOPHER P. AUSTIN, M.D. DIRECTOR, NCATS U.S. NATIONAL INSTITUTES OF HEALTH BIO INTERNATIONAL.
Lorenzo Refolo & M-D Kerns
Branko Stefanovic Biomedical Sciences
What is CICATS? The University of Connecticut, in partnership with regional hospitals, state agencies, and community health care organizations, has.
Clinical and Translational Science Awards Program
How Chemoproteomics Can Enable Drug Discovery and Development
Consortium: National networks in 16 European countries.
Consortium: National networks in 16 European countries.
Center for Clinical and Translational Science
Presentation transcript:

Basic Translational Clinical New Pathways to Discovery Harmonization Target ID & Valid. Phases I-III Research Teams of Future Translational Cores Clinical Networks Molecular Libraries Clinical and Translational Science Awards { R & D NIH Roadmap: A Systems Approach Across the Research Spectrum Practice Screening/ Optimization Preclinical Fundamental Public-Private Partnerships PPP-Across the entire spectrum

NIH Roadmap Molecular Libraries Program: Assay Development for High Throughput Screening Mark Scheideler, Ph.D., Program Director Fong Wang, Ph.D., Scientific Analyst

Aims of the Program: Extract assays from ongoing research programs, and provide the resourcing needed to configure them for use in probe development projects. Encourage the development of novel assays and assay technologies.

Compound Repository Screening Centers Network Molecular Libraries Screening Center Network (MLSCN ) HTS Assays

Overall Capabilities of the Screening Center Network GPCRs Enzymes Proteases Protein-Protein interactions High Content Screening High-throughput Microscopy NMR-based methods Protein Translocation Complementary HTS Flow Cytometry Protein Kinases Ion channels Transporters Kalypsys BSL-3

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.